Does postoperative intravenous corticosteroid and intravenous beta blocker management prevent atrial fibrillation after cardiac surgery?

INTERVENTION: Trade Name: Solu‐Cortef 100mg inj kuiva‐aine ja liuotin liuosta varten Product Name: Solu‐Cortef Product Code: 420596 Pharmaceutical Form: Concentrate and solvent for solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Seloken 1mg/ml inj, liuos Product Name: Seloken Product Code: 422022 Pharmaceutical Form: Solution for injection CONDITION: new onset atrial fibrillation and paroxysmal atrial fibrillation Therapeutic area: Diseases [C] ‐ Cardiovascular Diseases [C14] PRIMARY OUTCOME: Main Objective: The main objective of the trial is to investigate whether postoperative corticosteroid and betablocker management prevents new‐onset atrial fibrillation or; activation of paroxysmal atrial fibrallation immediately after coronary artery bypass surgery and aortic valve surgery. Primary end point(s): Patient stays in sinus rhythm for three days postoperatively or; patient gets atrial fibrillation during first three postoperative days. Secondary Objective: Not applicable Timepoint(s) of evaluation of this end point: Three postoperative days SECONDARY OUTCOME: Secondary end point(s): none Timepoint(s) of evaluation of this end point: none INCLUSION CRITERIA: Coronary artery bypass surgery or aortic valve surgery, adult, willing to participate, not in chronic atrial fibrillation preoperatively Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 120